|Project name:||Project category:||Kind of research:||Country:||Principle investigator:|
|Clinical research||Europe||Prof. Kors van der Ent|
HIT-CF Europe is a research project which aims to provide better treatment and better lives for people with CF and rare mutations. To achieve this, drug candidates of several companies will first be tested in the laboratory on patient-derived mini-intestines (organoids). Secondly, based on the reaction in the organoids, a smaller group of patients will be assigned to studies (clinical trials) with one of the drug candidates.
Organoids are cell cultures that grow in a culture dish, and look similar to the organ from which they are derived. Intestinal organoids can therefore also be called mini-intestines. To make intestinal organoids for the HIT-CF Europe project, rectal tissue samples (biopsies) will be obtained. This procedure is not painful and will take 5-10 minutes. Because organoids are made from stem cells, they contain the same mutations as the person from whom the biopsies are derived. The drug candidates target the basic defect of CF, and the organoids will be used to test on which mutations the drugs have a positive effect.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 755021
|Project amount (€):||6.700.000|